Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The NMDA receptor redox site is a critical allosteric regulatory region located on the extracellular domains of the N-methyl-D-aspartate (NMDA) receptor, primarily involving specific cysteine residues on the GluN1 and GluN2A subunits (Choi et al., 2000). This site functions as a molecular sensor for the cellular redox environment; the oxidation of these cysteine residues to form disulfide bridges or their S-nitrosylation decreases the receptor's open-channel probability and calcium conductance, whereas their reduction enhances receptor activity (Aizenman et al., 1989). In pathological states such as ischemic stroke, traumatic brain injury, and epilepsy, excessive reduction of this site can lead to NMDA receptor overactivation, resulting in excitotoxicity and neuronal death (Sanchez et al., 2000). Conversely, pharmacological modulation of the redox site using mild oxidants or S-nitrosylating agents, such as NitroMemantine, offers a therapeutic pathway to dampen pathological NMDAR activity while sparing the receptor's essential roles in synaptic plasticity and cognitive function (Lipton et al., 2015). This site represents a promising target for neuroprotective drugs that aim to achieve a finesse blockade of the receptor compared to traditional pore-blocking antagonists.
Redox modulation of the NMDA receptor involves the reversible oxidation and reduction of specific cysteine residues (e.g., Cys744 and Cys798 on GluN1, Cys399 on GluN2A) located on the extracellular domains. Oxidation of these sulfhydryl groups to form disulfide bonds or their modification via S-nitrosylation induces a conformational change that decreases the frequency of channel opening and reduces calcium influx. Conversely, reduction of these disulfide bonds by reducing agents increases the receptor's open-channel probability, enhancing excitatory currents and potentially leading to excitotoxic neuronal injury.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate receptor, ionotropic, NMDA-type – redox site (NMDAR redox site).